SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): January 27, 2004
Sirna Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
| | | | |
Delaware | | 0-27914 | | 34-1697351 |
(State or other jurisdiction of incorporation) | | (Commission File No.) | | (I.R.S. Employer Identification Number |
2950 Wilderness Place
Boulder, Colorado 80301
(Address of principal executive offices)
Registrant’s telephone number, including area code: (303) 449-6500
N/A
(Former name or former address, if changed since last report.)
ITEM 5. OTHER EVENTS
Sirna Therapeutics, Inc. (the “Company”) announced on Tuesday, January 27, 2004 a collaboration with Eli Lilly & Company (NYSE: LLY) to develop RNA-interference (RNAi) therapeutics. During the eighteen-month collaboration, Lilly and Sirna will jointly investigate Sirna’s proprietary modified small interfering RNAs (siRNAs) against specific oncology targets provided by Lilly.
A copy of the press release issued by the Company on Tuesday, January 27, 2004 is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
This Current Report on Form 8-K and the attached press release contain forward-looking statements that involve risks and uncertainties, and actual events or results may differ materially. These risk factors include actions by the U.S. Food and Drug Administration, technological advances, ability to obtain rights to technology, ability to obtain and enforce patents, ability to commercialize and manufacture products and general economic conditions. These and additional risk factors are identified in the company’s Securities and Exchange Commission filings, including the Forms 10-K and 10-Q and in other SEC filings.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS
| | |
| (c) Exhibits | | |
| |
| 99.1 | | Press Release issued by the Company on January 27, 2004. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: January 27, 2004
| | |
SIRNA THERAPEUTICS, INC . (Registrant) |
| |
By: | | /s/ Howard W. Robin |
Name: | | Howard W. Robin |
Title: | | President and Chief Executive Officer |
EXHIBIT INDEX
| | |
Exhibit No. | | Description of Exhibit |
| |
99.1 | | Press Release issued by the Company on January 27, 2004. |
